SRSilvia Romero-Murillo

Silvia Romero-Murillo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Silvia Romero-Murillo has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Restoration of PP2A AαB56αC trimer formation by RPT04402 molecular glue in high-grade uterine cancer

    by Irene Peris, Terrance J. Haanen, Alexander Day, Jiang Hu, Catherine Callahan, Gabrielle Hodges-Onishi, Kaitlin P. Zawacki, Brian Tran, Alexis Harold, Amanda Dowdican, et al.

    The incidence and mortality of high-grade endometrial cancers are increasing, and heterozygous hotspot mutations in PPP2R1A are drivers of the most aggressive forms of uterine cancer. PPP2R1A encodes the Aα scaffolding subunit of the heterotrimeric phosphatase PP2A. These recurrent mutations, specifically at the Pro 179 and Ser 256 residues, disrupt the binding of tumor-suppressive substrate-directing B56 and B55 subunits to the PP2A scaffolding subunit while maintaining binding to other regulatory subunits. Here, we identified a series of molecular glues that correct PP2A trimer formation in the context of the P179R (Pro 179 →Arg) and S256F (Ser 256 →Phe) mutants. A small-molecule library was designed to fit into the pocket at the binding interface of the Aα/B56α/C heterotrimer. The lead molecule, RPT04402, promoted B56α heterotrimerization to the Aα P179R and Aα S256F mutant scaffolds. In mice, RPT04402 treatment drove tumor regressions and extended median survival in multiple independent mutant cell lines and patient-derived xenografts, proving a robust single-agent activity. This activity was abrogated upon knockout of B56α. Combined, these data demonstrate that PP2A molecular glues are a promising first-in-class therapy that might benefit patients with PPP2R1A mutant uterine cancer by targeting a driver of this aggressive disease.

  • Open Access

    Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α‐synuclein preformed fibrils‐induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines

    by Paz Cartas‐Cejudo, Marina De Miguel, Leire Extramiana, Mercedes Lachén‐Montes, Silvia Romero‐Murillo, Djordje Gveric, Joaquín Fernández‐Irigoyen, Enrique Santamaría

    Parkinson's disease (PD) is the second most common neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons originating in the substantia nigra (SN) pars compacta and projecting to other brain regions, giving rise to motor and non‐motor symptoms. Despite significant progress in understanding the molecular and cellular disruptions associated with PD, there remains an unmet clinical need for effective therapies. In this study, proteomic analysis of the olfactory tract (OT) in controls with no known neurological history ( n = 17) and PD subjects ( n = 21) revealed Lewy body disease (LBD) stage‐dependent proteostatic impairment, accompanied by progressive modulation of the alpha‐synuclein (α‐syn) functional interactome. Differential OT omic profiles were used in a computational drug repurposing approach, revealing the HDAC1 inhibitor pyroxamide as one of the top drug candidates with in silico potential to restore altered OT omic profiles. To explore the potential therapeutic effects of pyroxamide, in vitro assays were performed using α‐syn preformed fibrils (PFFs). Pyroxamide treatment reduced α‐syn PFFs‐induced toxicity in olfactory epithelial, microglial and dopaminergic neuronal cell lines, producing a protective effect against hydrogen peroxide‐induced damage exclusively in brain‐derived cell types. Mechanistically, the mitigating effects of pyroxamide were attributable, at least in part, to the regulation of Bax‐1 and sirtuin 1 (SIRT1) protein expression, along with alterations in the mRNA levels of NEF2L2, IL1B, and TNF‐α. These findings confirm the suitability of omics profiles in drug repurposing workflows against PD, offering valuable insights into the potential of HDAC1 inhibitors in the therapeutic pipeline of PD.

  • Open Access

    Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α-synuclein preformed fibrils-induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines

    by Paz Cartas-Cejudo, Marina De Miguel, Leire Extramiana, Mercedes Lachén-Montes, Silvia Romero-Murillo, Djordje Gveric, Joaquín Fernández-Irigoyen, Enrique Santamaria

    Parkinson’s disease (PD) is the second most common neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons originating in the substantia nigra (SN) pars compacta and projecting to other brain regions, giving rise to motor and non-motor symptoms. Despite significant progress in understanding the molecular and cellular disruptions associated with PD, there remains an unmet clinical need for effective therapies. In this study, proteomic analysis of the olfactory tract (OT) in controls with no known neurological history (n=17) and PD subjects (n=21) revealed Lewy body disease (LBD) stage-dependent proteostatic impairment, accompanied by progressive modulation of the alpha-synuclein (α-syn) functional interactome. Differential OT omic profiles (OMS) were used in a computational drug repurposing approach, reveling the HDAC1 inhibitor pyroxamide as one of the top drug candidates with in silico potential to restore altered OMS. To explore the potential therapeutic effects of pyroxamide, in vitro assays were performed using α-syn preformed fibrils (PFFs). Pyroxamide treatment reduced α-syn PFFs-induced toxicity in olfactory epithelial, microglial and dopaminergic neuronal cell lines, producing a protective effect against hydrogen peroxide-induced damage exclusively in brain-derived cell types. These findings confirm the suitability of omics profiles in drug repurposing workflows against PD, offering valuable insights into the potential of HDAC1 inhibitors in the therapeutic pipeline of PD. Graphical

  • Proteomic interrogation of the human olfactory system: the road ahead

    by Elena Anaya-Cubero, Paz Cartas-Cejudo, Marina De Miguel, Leire Extramiana, Silvia Romero-Murillo, Mercedes Lachén-Montes, Joaquín Fernández-Irigoyen, Enrique Santamaría

  • Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

    by Irene Peris, Silvia Romero-Murillo, Elena Martínez-Balsalobre, Caroline C. Farrington, Elena Arriazu, Nerea Marcotegui, Marta Jiménez-Muñoz, Cristina Alburquerque-Prieto, Andrea Torres-López, Vicente Jose Fresquet, et al.

    Venetoclax combination therapies are becoming the standard of care in acute myeloid leukemia (AML). However, the therapeutic benefit of these drugs in older/unfit patients is limited to only a few months, highlighting the need for more effective therapies. Protein phosphatase 2A (PP2A) is a tumor suppressor phosphatase with pleiotropic functions that becomes inactivated in ∼70% of AML cases. PP2A promotes cancer cell death by modulating the phosphorylation state in a variety of proteins along the mitochondrial apoptotic pathway. We therefore hypothesized that pharmacological PP2A reactivation could increase BCL2 dependency in AML cells and, thus, potentiate venetoclax–induced cell death. Here, by using 3 structurally distinct PP2A-activating drugs, we show that PP2A reactivation synergistically enhances venetoclax activity in AML cell lines, primary cells, and xenograft models. Through the use of gene editing tools and pharmacological approaches, we demonstrate that the observed therapeutic synergy relies on PP2A complexes containing the B56α regulatory subunit, of which expression dictates response to the combination therapy. Mechanistically, PP2A reactivation enhances venetoclax-driven apoptosis through simultaneous inhibition of antiapoptotic BCL2 and extracellular signal-regulated kinase signaling, with the latter decreasing MCL1 protein stability. Finally, PP2A targeting increases the efficacy of the clinically approved venetoclax and azacitidine combination in vitro, in primary cells, and in an AML patient-derived xenograft model. These preclinical results provide a scientific rationale for testing PP2A-activating drugs with venetoclax combinations in AML.